Subscribe
img_2709
26 November 2019Big PharmaTom Phillips

LSPN Europe: understand our business models, say in-house lawyers

The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.

More on this story

Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.
Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team